Skip navigation

LifeArc Appointments Strengthen Board of Trustees

06 December 2017

London, UK, 05 December 2017: LifeArc®, the medical research charity, has strengthened its board by appointing three new trustees: Aisling Burnand, MBE, Chief Executive of the Association of Medical Research Charities (AMRC); Daniel Morgan; and Jessica Mann, Company Head, Cardiovascular Development Consulting, GmbH.
 
LifeArc pioneers new ways to turn great science into greater patient impact. The charity drives medical innovation from within its own research laboratories and in collaboration with a network of partners. It also created two new funds to help translate science into new therapeutics and diagnostics for patients. LifeArc’s trustees have extensive expertise in biomedical sciences, finance, law and medicine to effectively govern the charity’s work.
 
Dr John Stageman, Chairman, LifeArc, said: “I am extremely pleased to welcome Aisling, Daniel and Jessica to LifeArc’s board of trustees. The skills and experience of our trustees are important in providing good governance and strategic guidance. LifeArc has embarked on an ambitious new strategy to drive medical innovation. The different and complementary skills our new trustees bring will strengthen and diversify the board and are invaluable in helping us deliver our charitable objects.”
 
Aisling Burnand has been Chief Executive of AMRC since September 2014, and held a similar role at the BioIndustry Association, where she championed UK biosciences. She received an MBE in 2007 for services to science.
 
Daniel Morgan has over 20 years’ experience of private capital markets, including venture investment in life sciences. He is a Member of the Institute of Chartered Accountants in England and Wales.
 
Jessica Mann is a cardiovascular specialist, with over 20 years’ experience in clinical leadership and advisory roles. She co-founded clinical trials database TrialReach (now Antidote). In her current role she supports biotechnology and pharmaceutical companies and investment funds in the assessment and development of drugs and gene therapy.